The authors have no commercial interests in any products mentioned in this article We would like to thank Doyle et al for their interest in our reported series of four cases. 1 We agree that logMAR visual acuity measurements should be encouraged especially in situations where measurements using a Snellen chart may not be sensitive enough to recognise a change in the acuity. In keeping with the standard practice we routinely record logMAR visual acuities for all patients undergoing PDT. In the text of our report we have reported the decline in visual acuity in terms of the drop in the number of letters read on the logMAR chart. This is similar to the way results were summarised in the TAP study 2 where reduction of visual acuity by fewer than 15 letters over a 24-month period was considered as beneficial effect of the treatment. Furthermore, although one of our patients lost only 14 letters, this happened rapidly over a 9-month period in spite of closure of the CNV which is not strictly comparable with the beneficial outcome reported in the TAP study.
Doyle et al have said that nowhere in the paper is the actual logMAR visual acuity shown. We would like to draw their attention to Figures 2 and 3 in our report that clearly mention the actual logMAR visual acuity values for that case. We feel that using the reciprocal of actual logMAR values appropriately illustrates graphically in Figure 1 the steep decline in visual acuity as a downward slope. We do not think that adding a table showing logMAR visual acuities would have added to our message from this small case series that in certain cases visual acuity could decline fairly rapidly in spite of a 'successful' PDT treatment. 
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